Welcome to our dedicated page for Pulmonx Corporation news (Ticker: LUNG), a resource for investors and traders seeking the latest updates and insights on Pulmonx Corporation stock.
Pulmonx Corporation (Nasdaq: LUNG) is a leading medical technology company dedicated to transforming the treatment of severe lung diseases. The company's primary focus is on developing life-changing, minimally invasive technologies to enhance the lives of patients suffering from emphysema, a form of Chronic Obstructive Pulmonary Disease (COPD). Pulmonx's flagship product, the Zephyr Endobronchial Valve (EBV), offers a non-surgical treatment option to reduce the volume of diseased lung tissue, thereby improving breathing and increasing patients' activity levels. This innovative approach provides a viable alternative to lung volume reduction surgery and lung transplantation, which have significant limitations and risks.
Pulmonx also offers the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform, which work in tandem with the Zephyr Valve to optimize patient selection and treatment outcomes. These technologies are pivotal in managing advanced emphysema and are commercially available in over 25 countries.
In recent financial updates, Pulmonx reported robust growth, with total worldwide revenue reaching $17.2 million in Q2 2023, marking a 23% increase compared to the same period in 2022. U.S. revenue alone saw a 28% rise, highlighting the strong domestic market traction. The company's ongoing commercial success and adoption of Zephyr Valve procedures are driving this growth.
Pulmonx's fiscal health remains strong, with a gross profit of $12.7 million in Q2 2023 and a gross margin of 74%. Operating expenses rose to $29.2 million, mainly due to increased clinical and development costs associated with the AeriSeal program, alongside higher selling, legal, and stock-based compensation expenses. Despite a net loss of $16.2 million for the quarter, the company maintains significant cash reserves, totaling $147.6 million as of June 30, 2023.
Looking ahead, Pulmonx has raised its 2023 revenue guidance to $64-$66 million, reflecting an expected growth rate of 19%-23% over the previous year. Operating expenses for the year are projected to be between $112 million and $114 million. The company remains committed to expanding its global market reach and meeting the substantial unmet clinical needs of patients with severe emphysema.
For investors and stakeholders, Pulmonx represents a dynamic and promising entity in the medtech space, continually striving to enhance patient outcomes through groundbreaking innovations in pulmonary care.
Pulmonx Corporation (Nasdaq: LUNG), a leader in minimally invasive treatments for severe lung disease, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022, at 12:40 PM PT. A live and archived webcast will be available on the company's investor website. Pulmonx is known for its innovative Zephyr Valve, which treats patients with severe emphysema/COPD and has received FDA breakthrough device designation. The valve is commercialized in over 25 countries, with more than 100,000 units used to date.
Pulmonx Corporation (Nasdaq: LUNG) will release its Q1 2022 financial results on May 3, 2022, after market close. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results. Investors can participate by calling (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 2575271. The event will also be accessible via a live and archived webcast on the company's website.
Pulmonx Corporation (LUNG) reported strong financial results for Q4 and full year 2021, with Q4 revenue reaching $13.7 million (+39%) and full-year revenue at $48.4 million (+48%). The company achieved a gross margin of 74.8% in Q4, up from 72.0% in 2020. Operating expenses increased by 38% to $22.6 million in Q4, leading to a net loss of $13.0 million. For 2022, Pulmonx forecasts revenues between $55 million and $60 million, despite ongoing COVID-19 impacts.
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in the Citi 2022 Virtual Healthcare Conference on February 24, 2022, at 8:45 AM PT / 11:45 AM ET. The event will feature a fireside chat with the company's leaders discussing their innovative treatments for severe lung disease. A live and archived webcast will be available on the Investors section of Pulmonx's website. Pulmonx specializes in minimally invasive solutions, notably the Zephyr® Endobronchial Valve, which has been approved by the FDA and is available in over 25 countries, treating more than 25,000 patients.
Pulmonx Corporation (Nasdaq: LUNG) will release its financial results for Q4 and full year 2021 on February 23, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET for discussion and analysis of the results. Investors can participate via phone or through a live webcast available on Pulmonx's investor website. Pulmonx is recognized for its minimally invasive solutions for severe lung disease, including the Zephyr® Endobronchial Valve, which has treated over 25,000 patients globally.
Pulmonx Corporation (Nasdaq: LUNG) has announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 7:30 a.m. EST. The presentation will be accessible via a live and archived webcast on the company’s investors webpage.
Pulmonx is recognized for its innovative solutions for severe lung disease, notably the Zephyr® Endobronchial Valve, which has received FDA pre-market approval. The valve is currently available in over 25 countries, having been used in more than 25,000 patients worldwide.
Pulmonx Corporation (Nasdaq: LUNG) will participate in the 33rd Annual Piper Sandler Healthcare Conference from November 29 to December 2, 2021. The management team will hold investor meetings on December 1, 2021, and a pre-recorded fireside chat will be available on the company’s website starting November 22, 2021. Pulmonx is recognized for its minimally invasive treatments for severe lung disease, including the Zephyr® Endobronchial Valve, which has been used in over 100,000 procedures worldwide. For more information, visit Pulmonx Investors.
Pulmonx Corporation (Nasdaq: LUNG) announced its participation in two virtual investor conferences. Management will present at the Stifel 2021 Virtual Healthcare Conference on November 16, 2021, at 12:20 PM PT / 3:20 PM ET, available via webcast on their website. Additionally, they will attend investor meetings at the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum on November 18, 2021. Pulmonx specializes in minimally invasive treatments for severe lung diseases, including emphysema and COPD, with over 100,000 Zephyr Valves used globally.
Pulmonx Corporation (LUNG) reported a 25% increase in worldwide revenue for Q3 2021, totaling $13.3 million, compared to $10.6 million in Q3 2020. The gross margin improved to 73% from 70% year-over-year. U.S. revenue rose 28% to $6.9 million. Operating expenses surged 52% to $19.5 million, leading to a net loss of $10.2 million or $0.28 per share. Pulmonx maintains its full-year revenue guidance of $49 to $51 million, amid ongoing COVID-19 uncertainties.
Pulmonx Corporation (Nasdaq: LUNG) will release its third quarter 2021 financial results on November 2, 2021, post-market. A conference call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can join the call by dialing (833) 614-1518 domestically or (270) 823-1072 internationally, using Conference ID: 9545716. Pulmonx is known for its minimally invasive treatments for lung diseases, including the Zephyr® Endobronchial Valve, which has been used in over 25,000 patients worldwide.
FAQ
What is the current stock price of Pulmonx Corporation (LUNG)?
What is the market cap of Pulmonx Corporation (LUNG)?
What is Pulmonx Corporation's primary focus?
What products does Pulmonx offer?
How does the Zephyr Endobronchial Valve work?
What recent financial achievements has Pulmonx reported?
What is Pulmonx's financial outlook for 2023?
In which markets are Pulmonx's products commercially available?
What are the key benefits of the Zephyr Valve treatment?
How does Pulmonx support its products' adoption in the medical community?
Who is the current interim CFO of Pulmonx Corporation?
Where can I find more information about Pulmonx Corporation?
